Watch ANRO. Know when insiders buy.
One email the day a filing lands. Free.
ANRO
Alto Neuroscience, Inc.
35.55
−0.85 −2.34%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
27
FLAG · shorts 27
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.4BP/E —DIV YIELD —FCF YIELD -4.93%REV TTM —NET INCOME −$84.2MNET CASH $233.5M52W 3.56 – 36.64SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$29.1M | −$27.6M | — | -0.65 | −$19.8M | $0 | −$19.8M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$27.1M | −$26.2M | — | -0.80 | −$27.1M | $556K | −$27.6M | Aug 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$17.1M | −$16.2M | — | -0.45 | −$11.5M | $0 | −$11.5M | Mar 16 |
| Q3 2025 · Sep 30 | — | — | — | −$15M | −$14.2M | — | -0.52 | −$9.9M | $0 | −$9.9M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$18.7M | −$17.7M | — | -0.65 | −$13.8M | $0 | −$13.8M | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$15.7M | −$15.2M | — | -0.56 | −$16.6M | $24K | −$16.6M | Aug 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$17M | −$15.2M | — | -0.56 | −$13M | $506K | −$13.5M | Mar 16 |
| Q3 2024 · Sep 30 | — | — | — | −$18.9M | −$16.8M | — | -0.62 | −$11.7M | $1M | −$12.7M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$18.3M | −$16M | — | -0.60 | −$11.7M | $340K | −$12M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$14.4M | −$13.4M | — | -0.76 | −$11M | $224K | −$11.2M | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$11.8M | −$11.2M | — | -2.98 | −$11.5M | $352K | −$11.9M | Mar 20 |
| Q3 2023 · Sep 30 | — | — | — | −$9.7M | −$9.1M | — | -2.44 | −$7.8M | $43K | −$7.8M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$66.4M | −$63.2M | — | -2.19 | −$51.8M | $24K | −$51.8M | — | — |
| FY2024 · to Dec 31 | — | — | −$68.6M | −$61.4M | — | -2.50 | −$47.4M | $2.1M | −$49.5M | — | — |
| FY2023 · to Dec 31 | — | — | −$37.8M | −$36.3M | — | -9.73 | −$33.4M | $470K | −$33.9M | — | — |
Every number comes from Alto Neuroscience, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.